|Trial status||Trial open for recruitment|
Interventional with experimental drug
|Phase||Trial phase 2|
|Inclusion criteria||-DLBCL CD20 +de novo or transformed from low grade NHL or follicular lymphoma grade 3b -relapsed or refractory : Patients eligible for ASCT who failed to achieve a CR after at least one salvage therapy Or patients in first relapse after ASCTOr patients|
The New Jules Bordet Institute, located on the university campus of the ULB in Anderlecht, is ready and will soon welcome its first patients. A new state-of-the-art hospital entirely dedicated to the fight against cancer.